Breast Cancer Chemotherapy and Metastatic Disease Options

Breast cancer chemotherapy is given either after surgery (adjuvant) or before it (neoadjuvant). The standard of care is anthracycline-based chemotherapy, usually combined with a taxane over six to eight cycles. In metastatic breast cancer, chemotherapy, typically six to eight courses, is the mainstay except in hormone receptor positive, HER2-negative disease, where endocrine therapy with a CDK4/6 inhibitor usually comes first; about 30 to 35 per cent of patients respond very well. When disease persists, immunotherapy, second-line and third-line chemotherapy, CDK4/6 inhibitors and gene sequencing of the tumour extend the options.

Those are the systemic treatment principles Dr. Jalaj Baxi, Director Surgical Oncology, Fortis Hospital, Noida, India, set out in his masterclass, and they were tested in the questions that followed, including a metastatic case sent in by a doctor during the session. This article covers chemotherapy timing and safety, hormonal, targeted and immunotherapy, and the management of metastatic disease. Where these treatments sit in the overall pathway is explained in the guide to breast cancer diagnosis and management for general practitioners.

Breast cancer chemotherapy: adjuvant vs neoadjuvant

The two terms describe timing, not drugs:

• Adjuvant chemotherapy is given after surgery, to eliminate microscopic disease that may remain.
• Neoadjuvant chemotherapy is given before surgery, to shrink the tumour so that it can be removed, or removed with a smaller operation.

Who needs adjuvant chemotherapy

Dr. Baxi's starting position is that all patients with early breast cancer will require chemotherapy. The standard of care is anthracycline-based chemotherapy, usually combined with a taxane over six to eight cycles.

There is one exception. A small subset of patients with early disease, T1 or T2 tumours with no nodal involvement (T1 to T2 N0), may avoid chemotherapy if further testing shows favourable disease characteristics. Dr. Baxi put it simply: only a subset of patients with favourable disease may safely omit chemotherapy. Multigene expression assays performed on the tumour tissue are commonly used to identify these patients, particularly in hormone receptor positive, HER2-negative disease. How these assays are used is covered in can chemotherapy be avoided in early breast cancer.

Who needs neoadjuvant chemotherapy

Neoadjuvant chemotherapy is indicated in three groups:

1. Triple-negative breast cancer, even when operable.
2. HER2-positive breast cancer, even when operable.
3. Locally advanced breast cancer, where chemotherapy is followed by surgery once the tumour has come down.

Hormone receptor positive disease takes the opposite route in Dr. Baxi's approach: surgery first, then chemotherapy. The surgical options that follow neoadjuvant treatment, and the radiotherapy that completes local control, are covered in breast surgery, the axilla and when radiotherapy follows.

How the treatments combine in early breast cancer

In early breast cancer, Dr. Baxi's algorithm links the operation to everything that follows. Breast-conserving therapy is followed by radiotherapy and chemotherapy, and then, depending on the hormone receptor and HER2 status, by hormonal therapy or targeted therapy. A patient with early disease may therefore receive four modalities in sequence, each chosen for a different reason: surgery and radiotherapy for local control, chemotherapy for microscopic spread, and hormonal or targeted therapy for the tumour's specific biology.

Hormonal therapy, targeted therapy and immunotherapy

Beyond chemotherapy, three further classes of treatment are matched to the tumour's biology:

• Hormonal therapy for hormone receptor positive disease, that is, ER-positive or PR-positive cancers. These drugs, such as tamoxifen or the aromatase inhibitors, block the hormonal signal that drives the cancer's growth.
• Targeted therapy for HER2-positive disease. The standard HER2-directed agent is trastuzumab, a monoclonal antibody against the HER2 receptor.
• Immunotherapy, drugs that enable the patient's immune system to attack the cancer. In breast cancer, immune checkpoint inhibitors are used mainly in triple-negative disease.

Dr. Baxi noted that these treatments are used more commonly in advanced or metastatic breast cancer. Hormonal and HER2-directed therapy are also standard treatment in early breast cancer when the relevant receptors are positive. He was candid about the limits of a single session: targeted therapy and immunotherapy could each fill an hour on their own. Costs for these treatments are on the chemotherapy cost page and the immunotherapy cost page.

Making chemotherapy safe: supervision and bone marrow suppression

A doctor in the session asked how reactions to anticancer drugs can be prevented and mortality reduced. Dr. Baxi's answer reframed the risk. Death from chemotherapy is a rare event, and when it occurs it is almost always due to bone marrow suppression: the fall in white cells, red cells and platelets that chemotherapy causes.

The protection is early detection. Chemotherapy should be given under close supervision, so that bone marrow suppression is caught early and a possible death is avoided. In practice, blood counts are checked before each cycle, and fever in a patient with a low white cell count (febrile neutropenia) is treated as an emergency. For doctors who share the care of patients receiving chemotherapy, this is the central safety task.

Metastatic breast cancer treatment

In metastatic breast cancer, Dr. Baxi's management plan centres on chemotherapy. For hormone receptor positive, HER2-negative disease without immediately life-threatening organ involvement, international guidelines place endocrine therapy with a CDK4/6 inhibitor first, ahead of chemotherapy. Where chemotherapy is used, the question is which regimen, for how long, and what to expect.

Choosing the regimen

Dr. Baxi was asked about a woman in her sixties with metastatic breast cancer in whom mastectomy was not feasible and chemotherapy had been started. He explained that the regimen depends on the tumour's biology: whether it is ER positive, PR positive or HER2 positive decides the type of treatment. Most of the time the regimen is a combination, and where the tumour is HER2 positive, HER2-directed treatment should be included. Chemotherapy can also be combined with hormonal therapy. International guidelines generally advise giving hormonal therapy after chemotherapy, or as maintenance, rather than at the same time.

How many cycles

Dr. Baxi's figure is six to eight courses of chemotherapy. HER2-directed treatment in HER2-positive disease takes longer, around 20 cycles in his figure. In metastatic disease, HER2-directed therapy usually continues for as long as the cancer remains controlled.

What response to expect

Success depends on the individual patient's response. Dr. Baxi cited published figures that 30 to 35 per cent of patients with metastatic breast cancer respond very well to treatment. Other management plans also depend on that response. If the patient responds very well, the metastases can be treated as well and surgery can be done. Metastatic disease is therefore not automatically a palliative-only diagnosis: a good response can reopen local treatment.

When chemotherapy fails: second-line options

The same doctor asked a follow-up question: what if the patient is still symptomatic after the eighth course of chemotherapy? Dr. Baxi described four routes:

1. Add immunotherapy. He called immunotherapy the next line. Immune checkpoint inhibitors are approved in metastatic breast cancer mainly for triple-negative disease that expresses PD-L1.
2. Change the chemotherapy. Second-line and third-line regimens are available.
3. CDK4/6 inhibitors. These oral drugs block cyclin-dependent kinases 4 and 6, proteins that drive cell division. They are used together with hormonal therapy in hormone receptor positive, HER2-negative advanced breast cancer.
4. Next-generation sequencing (NGS). The tumour should be tested again, now by NGS, which reads many cancer genes at once. Gene sequencing identifies newer drugs likely to be effective in that particular patient.

The last point reflects a shift in how resistant disease is managed. Rather than moving empirically from one regimen to the next, the treating team re-examines the tumour's genetics and selects treatment against the mutations it finds.

Radiotherapy in advanced disease

Radiotherapy is not a substitute for surgery when surgery is feasible, but it remains standard after surgery for locally advanced disease and is widely used to control painful bone metastases and brain metastases, as set out in the article on breast cancer surgery and radiotherapy.

Where chemotherapy fits in the wider pathway

Systemic treatment is now planned from the first biopsy. The receptor result decides whether chemotherapy comes before or after surgery, which drugs are added, and what options remain if the disease returns. That is why the receptor tests described in breast cancer biopsy types, imaging and receptor testing matter as much as the diagnosis itself. Dr. Rajesh Kumar Jain's breast cancer treatment protocol by stage and subtype offers a comparable view from a separate masterclass. The full metastatic case, and the other questions doctors raised, are in the Live Discussion from this masterclass.